ACAD (Acadia Pharmaceuticals Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ACAD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-08-07 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-07-31 | Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | MIXED | — | — |
| 2026-06-29 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sell | — | — |
| 2026-06-02 | 667, L.P. | Director | A | — | — |
| 2026-06-01 | ELIZABETH A. GAROFALO | Director | M | — | — |
| 2026-06-01 | Laura Brege | Director | M | — | — |
| 2026-06-01 | James M Daly | Director | M | — | — |
| 2026-06-01 | Adora Ndu | Director | M | — | — |
| 2026-06-01 | EDMUND HARRIGAN | Director | M | — | — |
| 2026-06-01 | Jonathan Poole | Director | M | — | — |
| 2026-05-27 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sell | — | — |
| 2026-05-05 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-05-05 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | MIXED | — | — |
| 2026-04-07 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | MIXED | — | — |
| 2026-04-07 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-03-26 | Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | MIXED | — | — |
| 2026-03-26 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-03-26 | Adams Catherine Owen | Chief Executive Officer | MIXED | — | — |
| 2026-03-26 | Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | MIXED | — | — |
| 2026-03-26 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | MIXED | — | — |
| 2026-03-20 | Jonathan Poole | Director | A | — | — |
| 2026-03-10 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-03-10 | Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | A | — | — |
| 2026-03-10 | Thomas Garner | EVP, Chief Commercial Officer | A | — | — |
| 2026-03-10 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | A | — | — |
| 2026-03-10 | Adams Catherine Owen | Chief Executive Officer | A | — | — |
| 2026-03-10 | Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | A | — | — |
| 2026-02-10 | Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | MIXED | — | — |
| 2025-11-19 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-11-19 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | MIXED | — | — |
| 2025-11-12 | James M Daly | Director | Sell | — | — |
| 2025-09-16 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-09-03 | ELIZABETH A. GAROFALO | Director | Sell | — | — |
| 2025-08-19 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-06-05 | Laura Brege | Director | Sell | — | — |
| 2025-06-02 | EDMUND HARRIGAN | Director | M | — | — |
| 2025-06-02 | ELIZABETH A. GAROFALO | Director | M | — | — |
| 2025-06-02 | Adora Ndu | Director | M | — | — |
| 2025-06-02 | James M Daly | Director | M | — | — |
| 2025-06-02 | DANIEL B SOLAND | Director | M | — | — |
| 2025-06-02 | Laura Brege | Director | M | — | — |
| 2025-06-02 | BAKER BROS. ADVISORS LP | Director | A | — | — |
| 2025-05-19 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sell | — | — |
| 2025-05-19 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-05-02 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-05-02 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | MIXED | — | — |
| 2025-04-08 | Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-04-08 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | MIXED | — | — |
| 2025-03-26 | Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 39,487,463 | — |
| — | Director | 39,468,841 | — |
| — | Director | 39,452,627 | — |
| — | Director | 24,667,110 | — |
| — | Director | 3,609,489 | — |
| — | Director | 3,566,625 | — |
| — | Director | 1,468,014 | — |
| — | CEO | 186,555 | — |
| — | CEO | 175,549 | — |
| — | Director | 139,476 | — |
| — | EXEC VP, CFO AND CBO | 91,348 | — |
| — | EVP AND GC | 83,734 | — |
| — | EVP, CHIEF FINANCIAL OFFICER | 67,828 | — |
| — | EVP, COO, HEAD OF COMMERCIAL | 62,105 | — |
| — | President | 61,234 | — |
| — | EVP,General Counsel, Secretary | 46,901 | — |
| — | Director | 44,041 | — |
| — | EVP, DEVELOPMENT AND CMO | 43,550 | — |
| — | Director | 43,148 | — |
| — | Director | 36,127 | — |
| — | Director | 33,489 | — |
| — | Director | 32,908 | — |
| — | Chief Executive Officer | 26,444 | — |
| — | Director | 23,202 | — |
| — | EVP, Head of Research & Dev | 18,994 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACAD quote page; the site-wide leaderboard is on the insider transactions hub.